PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Carboplatin

Drugs in development · updated 30 October 2026

Carboplatin: clinical trials and development status

Other names and codes: Paraplatin, Kyxata

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Carboplatin is in 910 active clinical trials (recruiting or ongoing, phases I–III) for 172 diseases. The most advanced phase is III.

910Active trials
IIIMost advanced phase
172Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Carboplatin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 172 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Non-small-cell lung carcinomaIII215NCT06623422
Breast neoplasmIII76NCT07173751
Lung neoplasmIII72NCT04267848
Triple-negative breast neoplasmIII71NCT06279364
Ovarian neoplasmIII62NCT07743164
Head and neck squamous cell carcinomaIII56NCT00588770
Lung small cell carcinomaIII49NCT07802821
Endometrial neoplasmIII38NCT07198074
Fallopian tube neoplasmIII36NCT07743164
MetastasisIII31NCT07869836
NeoplasmIII25NCT07869836
Esophageal squamous cell carcinomaIII23NCT04460352
Uterine cervix neoplasmIII22NCT07216703
Head and neck neoplasmsIII21NCT06998069
Esophageal neoplasmIII20NCT07306663
Prostatic NeoplasmsIII17NCT06439225
CarcinomaIII13NCT06312137
Transitional cell carcinomaIII13NCT06524544
Bladder neoplasmIII12NCT07869836
Mouth NeoplasmsIII10NCT07827872
Oropharyngeal NeoplasmsIII10NCT05721755
Ovarian epithelial carcinomaIII10NCT06915025
Squamous cell carcinomaIII10NCT01706939
Adenocarcinoma of the lungIII9NCT04339218
Diffuse large B-cell lymphomaIII9NCT06792253
Laryngeal neoplasmIII7NCT05721755
MelanomaIII7NCT06008106
NeuroblastomaIII7NCT06172296
Biliary tract neoplasmIII6NCT05771480
Esophagus adenocarcinomaIII6NCT05188313

Everything on Carboplatin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch